Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug782 | Clinical Trial Matching Wiki | 0.58 |
drug1186 | Endoscopic management according to standard of care Wiki | 0.58 |
drug797 | Cloth Face Mask Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D010190 | Pancreatic Neoplasms NIH | 1.00 |
D018281 | Cholangiocarcinoma NIH | 0.82 |
D016889 | Endometrial Neoplasms NIH | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D013274 | Stomach Neoplasms NIH | 0.58 |
D012878 | Skin Neoplasms NIH | 0.58 |
D009423 | Nervous System Neoplasms NIH | 0.58 |
D007680 | Kidney Neoplasms NIH | 0.58 |
D016543 | Central Nervous System Neoplasms NIH | 0.58 |
D005909 | Glioblastoma NIH | 0.58 |
D008105 | Liver Cirrhosis, Biliary NIH | 0.58 |
D008113 | Liver Neoplasms NIH | 0.58 |
D007822 | Laryngeal Neoplasms NIH | 0.58 |
D041781 | Jaundice, Obstructive NIH | 0.58 |
D013736 | Testicular Neoplasms NIH | 0.58 |
D002292 | Carcinoma, Renal Cell NIH | 0.41 |
D004938 | Esophageal Neoplasms NIH | 0.41 |
D002583 | Uterine Cervical Neoplasms NIH | 0.41 |
D012004 | Rectal Neoplasms NIH | 0.41 |
D007565 | Jaundice, NIH | 0.41 |
D002761 | Cholangitis NIH | 0.41 |
D018358 | Neuroendocrine Tumors NIH | 0.41 |
D006258 | Head and Neck Neoplasms NIH | 0.33 |
D002277 | Carcinoma NIH | 0.29 |
D003110 | Colonic Neoplasms NIH | 0.29 |
D001943 | Breast Neoplasms NIH | 0.26 |
D008175 | Lung Neoplasms NIH | 0.24 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030153 | Cholangiocarcinoma HPO | 0.82 |
HP:0002896 | Neoplasm of the liver HPO | 0.58 |
HP:0008069 | Neoplasm of the skin HPO | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012114 | Endometrial carcinoma HPO | 0.58 |
HP:0100006 | Neoplasm of the central nervous system HPO | 0.58 |
HP:0010788 | Testicular neoplasm HPO | 0.58 |
HP:0009726 | Renal neoplasm HPO | 0.58 |
HP:0012174 | Glioblastoma multiforme HPO | 0.58 |
HP:0002613 | Biliary cirrhosis HPO | 0.58 |
HP:0100751 | Esophageal neoplasm HPO | 0.58 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.58 |
HP:0006753 | Neoplasm of the stomach HPO | 0.58 |
HP:0100605 | Neoplasm of the larynx HPO | 0.58 |
HP:0005584 | Renal cell carcinoma HPO | 0.41 |
HP:0100634 | Neuroendocrine neoplasm HPO | 0.41 |
HP:0100743 | Neoplasm of the rectum HPO | 0.41 |
HP:0030079 | Cervix cancer HPO | 0.41 |
HP:0000952 | Jaundice HPO | 0.41 |
HP:0030151 | Cholangitis HPO | 0.41 |
HP:0012288 | Neoplasm of head and neck HPO | 0.33 |
HP:0030731 | Carcinoma HPO | 0.29 |
HP:0003003 | Colon cancer HPO | 0.29 |
HP:0003002 | Breast carcinoma HPO | 0.26 |
HP:0100526 | Neoplasm of the lung HPO | 0.24 |
Navigate: Correlations HPO
There are 3 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearPancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis. However, treatment of PC in high-volume centers with the support of a multidisciplinary approach has widely demonstrated improvement both in terms of short- and long-term outcomes. The recent worldwide spread of Covid-19 pandemic significantly affected the healthcare systems of most countries in the world, particularly in red areas such as Italy, with more than 100.000 cases in a two-month time lapse. This inevitably reflected in a reorganization of hospital activities, including the diagnostic and therapeutic pathways for PC treatment. With the aim of giving an objective and real representation of the impact of Covid-19 on PC treatment, the investigator here propose a multicenter Italian observational study comparing a 6-month period before and during the Covid-19 pandemic. Only high-volume centers will be involved in the study. A comparison between the general, clinical, endoscopic and surgical outcomes will be performed by means of a global and month-by-month analysis between the two study periods.
In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
Description: Investigators will report the baseline demographic data (age, gender, nationality) of all patients.
Measure: Age, gender, nationality Time: 3 monthsDescription: Investigators will report the baseline data clinical data (indication for procedure, status of SARS-CoV-2 infection) of all patients.
Measure: Indication for procedure, status of SARS-CoV-2 infection Time: 3 monthsDescription: Investigators will report the baseline laboratory data (complete blood count and liver functions tests) of all patients.
Measure: Complete blood count and liver functions tests Time: 3 monthsDescription: Investigators will report the procedure related complications.
Measure: procedure related complications Time: 3 monthsDescription: Investigators will report wether the precautions lead to increase timing of the procedure
Measure: Effect of COVID-19 precautions on procedure time Time: 3 monthsDescription: Investigators will report wether the precautions affected staff number (increased or decreased)
Measure: Effect of COVID-19 precautions on staff number Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports